CancerDrs

Prostate Cancer clinical trials in Michigan

45 actively recruiting prostate cancer trials at 45 sites across Michigan.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Michigan:
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Trinity Health Medical Center - Brighton — Brighton, Michigan
  • University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
  • Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Michigan:
  • Veteran's Administration Medical Center - Ann Arbor — Ann Arbor, Michigan
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • McLaren Cancer Institute-Bay City — Bay City, Michigan
  • University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
  • Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Michigan:
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital — Chelsea, Michigan
  • OSF Saint Francis Hospital and Medical Group — Escanaba, Michigan
  • Genesys Hurley Cancer Institute — Flint, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …

Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Michigan:
  • Michigan Institute of Urology, PC — Troy, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Michigan:
  • Henry Ford Hospital ( Site 0015) — Detroit, Michigan
  • Cancer and Hematology Centers of Western Michigan ( Site 0005) — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Michigan:
  • Henry Ford Hospital ( Site 0015) — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Michigan:
  • BAMF Health — Grand Rapids, Michigan
  • Profound Research LLC — Royal Oak, Michigan
  • William Beaumont Hospital — Royal Oak, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in Michigan:
  • Research Site — Detroit, Michigan
  • Research Site — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Michigan:
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
  • Trinity Health Medical Center - Brighton — Brighton, Michigan
  • Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Michigan:
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital — Chelsea, Michigan
  • University of Michigan Health - Sparrow Lansing — Lansing, Michigan
  • Trinity Health Saint Mary Mercy Livonia Hospital — Livonia, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use ola…

Sponsor: VA Office of Research and Development
NCT ID: NCT04038502
Sites in Michigan:
  • VA Ann Arbor Healthcare System, Ann Arbor, MI — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on…

Sponsor: Zenith Epigenetics
NCT ID: NCT04986423
Sites in Michigan:
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurat…

Sponsor: Sun Pharmaceutical Industries Limited
NCT ID: NCT05422911
Sites in Michigan:
  • VA Ann Arbor Healthcare System — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 …

Sponsor: AstraZeneca
NCT ID: NCT07192614
Sites in Michigan:
  • Research Site — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

Sponsor: Syntrix Biosystems, Inc.
NCT ID: NCT06228053
Sites in Michigan:
  • University of Michigan — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production (castration-resis…

Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT06616155
Sites in Michigan:
  • University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
  • Karmanos Cancer Institute — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

The primary purpose of this study is to compare the quality of life (QOL) reported by prostate cancer patients 2 years after treatment with ultra-hypofractionated post-prostatectomy radiation therapy (also known as stereotactic body radiat…

Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT05038332
Sites in Michigan:
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Michigan:
  • Exelixis Clinical Site #65 — Detroit, Michigan
  • Exelixis Clinical Site #13 — Detroit, Michigan
View on ClinicalTrials.gov →

Showing 25 of 45 trials with sites in Michigan. See all prostate cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10